ALX Oncology Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALXO Nasdaq 2836 www.alxoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ALX Oncology Holdings Inc.

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - May 30th, 2025 6:00 am
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - May 20th, 2025 6:00 am
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - May 13th, 2025 6:00 am
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 6:30 am
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - May 2nd, 2025 6:00 am
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Apr 28th, 2025 5:51 am
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - Apr 25th, 2025 11:10 am
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints - Apr 25th, 2025 7:00 am
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - Apr 7th, 2025 6:00 am
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Mar 20th, 2025 7:55 am
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - Mar 7th, 2025 11:27 am
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 6th, 2025 2:01 pm
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives - Mar 5th, 2025 8:41 am
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - Mar 5th, 2025 6:00 am
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Feb 27th, 2025 6:00 am
February 2025 US Penny Stocks With Promising Prospects - Feb 19th, 2025 6:11 am
ALX Oncology to Host Virtual R&D Day on March 5, 2025 - Feb 18th, 2025 6:00 am
ALX Oncology Shares Drop 15% Following Positive Phase 2 - Jan 23rd, 2025 12:44 pm
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - Jan 23rd, 2025 6:00 am
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - Jan 22nd, 2025 2:01 pm